2024
Hypertension Control During the Coronavirus Disease 2019 Pandemic
Korves C, Peixoto A, Lucas B, Davies L, Weinberger D, Rentsch C, Vashi A, Young-Xu Y, King J, Asch S, Justice A. Hypertension Control During the Coronavirus Disease 2019 Pandemic. Medical Care 2024, 62: 196-204. PMID: 38284412, PMCID: PMC10922611, DOI: 10.1097/mlr.0000000000001971.Peer-Reviewed Original ResearchConceptsHypertension controlFollow-up intervalPrimary care clinic visitsFollow-up lengthVeterans Health AdministrationControlled hypertensionUncontrolled hypertensionGeneralized estimating equationsCohort of individualsStudy inclusion criteriaHealth careHealth AdministrationLonger follow-up intervalsBlood pressure measurementsAssessed associationsClinic visitsInclusion criteriaDecreased likelihoodEstimating equationsPrepandemic periodLow likelihoodCoronavirus diseaseFollow-upHypertensionIndividuals
2023
Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV
Torgersen J, Akers S, Huo Y, Terry J, Carr J, Ruutiainen A, Skanderson M, Levin W, Lim J, Taddei T, So‐Armah K, Bhattacharya D, Rentsch C, Shen L, Carr R, Shinohara R, McClain M, Freiberg M, Justice A, Re V. Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV. Pharmacoepidemiology And Drug Safety 2023, 32: 1121-1130. PMID: 37276449, PMCID: PMC10527049, DOI: 10.1002/pds.5648.Peer-Reviewed Original ResearchConceptsSevere hepatic steatosisHepatic steatosisHIV statusLiver attenuationHounsfield unitsPredictive valueRadiologist assessmentUS Veterans Health AdministrationNoncontrast abdominal CTVeterans Health AdministrationCross-sectional studySample of patientsNegative predictive valueReal-world studyPositive predictive valueAbdominal CTLiver fatTomography scanSteatosisCT imagesHealth AdministrationPharmacoepidemiologic studiesRadiologist reviewHIVPercent agreement
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisValidation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations
Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife 2022, 11: e78304. PMID: 35801699, PMCID: PMC9322982, DOI: 10.7554/elife.78304.Peer-Reviewed Original ResearchConceptsProstate cancer riskPolygenic risk scoresProstate cancerCancer riskOdds ratioMillion Veteran ProgramRisk scoreRisk stratification toolAge-specific absolute risksAfrican ancestry menCancer odds ratiosVeterans Health AdministrationCase-control studyNonaggressive prostate cancerProstate Cancer FoundationAge-specific riskAssociation of PRSPRS categoriesRisk-stratified screeningVeteran ProgramNational Cancer InstituteEuropean ancestry menStratification toolAbsolute riskEffect modificationPredicting counterfactual risks under hypothetical treatment strategies: an application to HIV
Dickerman BA, Dahabreh IJ, Cantos KV, Logan RW, Lodi S, Rentsch CT, Justice AC, Hernán MA. Predicting counterfactual risks under hypothetical treatment strategies: an application to HIV. European Journal Of Epidemiology 2022, 37: 367-376. PMID: 35190946, PMCID: PMC9189026, DOI: 10.1007/s10654-022-00855-8.Peer-Reviewed Original Research
2020
Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
King JT, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, Skanderson M, Hauser RG, Jacobson DA, Erdos J, Cho K, Ramoni R, Gagnon DR, Justice AC. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLOS ONE 2020, 15: e0241825. PMID: 33175863, PMCID: PMC7657526, DOI: 10.1371/journal.pone.0241825.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexVeterans Health AdministrationVACO IndexValidation cohortMedical administrative dataDevelopment cohortSARS-CoV-2 testing resultsMortality indexICD-10 diagnosis codesUS Veterans Health AdministrationSARS-CoV-2 infectionPre-existing medical conditionsCOVID-19 mortality riskPeripheral vascular diseaseCOVID-19 patientsCOVID-19 infectionCOVID-19 mortalitySARS-CoV-2Administrative dataLogistic regression modelsRace/ethnicityCohort subgroupsComorbidity indexOverall mortalityComorbid conditions
2019
Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States
Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 145-151. PMID: 30422912, PMCID: PMC6701630, DOI: 10.1097/qai.0000000000001904.Peer-Reviewed Original ResearchConceptsHepatitis C virusAlcohol-related diagnosesAdmission ratesMICU admissionAdmission riskC virusRelative riskIntensive care unit admission rateMedical intensive care unit admissionAge-adjusted admission ratesHCV mono-infected patientsIntensive care unit admissionVeterans Aging Cohort StudyHCV care providersCare unit admissionAging Cohort StudyAdjusted rate ratiosConfidence intervalsVeterans Health AdministrationUnhealthy alcohol useHIV monoHIV-/HCVUnit admissionCause hospitalizationHCV infection